# Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

> **NCT05896839** · PHASE1,PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 16 (estimated)

## Conditions studied

- Clinical Stage III Cutaneous Melanoma AJCC v8
- Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
- Clinical Stage IV Cutaneous Melanoma AJCC v8
- Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Metastatic Basal Cell Carcinoma
- Metastatic Carcinoma in the Skin
- Metastatic Melanoma
- Metastatic Merkel Cell Carcinoma
- Metastatic Skin Squamous Cell Carcinoma
- Unresectable Basal Cell Carcinoma
- Unresectable Melanoma
- Unresectable Merkel Cell Carcinoma
- Unresectable Skin Squamous Cell Carcinoma

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **BIOLOGICAL:** Ipilimumab
- **PROCEDURE:** Kidney Biopsy
- **PROCEDURE:** Magnetic Resonance Imaging
- **BIOLOGICAL:** Nivolumab
- **DRUG:** Prednisone
- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT05896839
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-24
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-01-31
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05896839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05896839, "Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer". Retrieved via MORVS 2026-10-28 from https://api.morvs.ai/clinical/NCT05896839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*